Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0KRTEV
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Monoclonal antibody B43-genistein-conjugate
|
|||||
| Synonyms |
B43-Genistein; B43-Genistein conjugate; Monoclonal antibody B43-Gen; B43-Gen
Click to Show/Hide
|
|||||
| Organization |
University of Minnesota; Bristol Myers Squibb Co.
|
|||||
| Drug Status |
Terminated in phase 1
|
|||||
| Indication |
In total 3 Indication(s)
Acute lymphocytic leukemia [ICD11:2B33]
Terminated in phase 1
Lymphoma [ICD11:2A85-2A90]
Terminated in phase 1
Non Hodgkin lymphoma [ICD11:2B33]
Terminated in phase 1
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
B-lymphocyte antigen CD19 (CD19)
|
Antigen Info | ||||
| Payload Name |
Genistein
|
Payload Info | ||||
| Therapeutic Target |
Pro-epidermal growth factor (EGF)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.